PHARMACOEPIDEMIOLOGIC STUDY ON ADVERSE REACTIONS OF ANTIEPILEPTIC DRUGS

被引:0
作者
IEIRI, I
HIRATA, K
HIGUCHI, S
KOJIMA, K
IKEDA, M
YAMADA, H
AOYAMA, T
机构
[1] KYUSHU UNIV HOSP, DEPT NEUROPSYCHIAT, HIGASHI KU, FUKUOKA 812, JAPAN
[2] KYUSHU UNIV, INST HLTH SCI, KASUGA, FUKUOKA 816, JAPAN
关键词
ANTIEPILEPTIC DRUG; SIDE EFFECT; PHARMACOEPIDEMIOLOGY; RISK FACTOR; DISCRIMINANT FUNCTION ANALYSIS;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The relationship between the occurrence of side effects (SEs) and drug factors, such as antiepileptic drugs (AEDs), daily dose, duration of treatment, drug combination pattern, total and free serum concentrations, metabolite per parent level ratio as an index of metabolism ability, and co-medicated drugs except AEDs were evaluated in 227 outpatients with epilepsy. The possible influences of certain physiological and/or the pathophysiological factors were also evaluated. SEs with 19 clinical signs were observed in 66.1% of all patients. There was no definite dose- or serum concentration-dependent increase in the incidence of SEs. Stepwise discriminant function analysis revealed that benzodiazepines (BZN) polytherapy with AEDs produced a higher incidence of somnolence and general fatigue than did any other AED or drug combination. The effects of various drug combination patterns on the incidence of SEs were also evaluated on the basis of observed frequencies. The incidence of somnolence was significantly higher in patients taking phenytoin (PHT) plus carbamazepine (CBZ) therapy, and in patients taking BZN plus either PHT, phenobarbital (PB) or CBZ therapy compared with patients taking either PHT, PB or CBZ therapy. Other responsible drug combination patterns were PHT plus valproic acid (VPA) therapy for mental function impairment, acetazolamide (AZM) polytherapy with PB or PHT for dry mouth, and CBZ plus BZN therapy for constipation. In this study, the stratifying points (occurrence limits) of SEs were detected in various variables such as the number of prescribed drugs, daily dose and serum concentrations. Interestingly, these limits are within the commonly accepted "therapeutic range" or "usual daily dose," and some of these limits shifted down when another AED was co-medicated. Furthermore, additional risk factors for patients who had clinical SEs, even though their serum concentrations or daily dose staved below the limits, were evaluated. However, this study confirms that variables related to drug therapy are more closely involved in the occurrence of SEs than variable patient characteristics, especially the number of prescribed drugs and the AEDs polytherapy with BZN. The incidence of almost SEs (eg. somnolence, weakness) significantly increased when three AEDs were co-medicated with BZN or AZM. Thus, it is emphasized that one or at most two AEDS, including psychopharmacological drugs, should be given to minimize the risk of SEs.
引用
收藏
页码:1280 / 1288
页数:9
相关论文
共 44 条
[1]   ADVERSE REACTIONS TO ANTIEPILEPTIC DRUGS - A MULTICENTER SURVEY OF CLINICAL-PRACTICE [J].
BEGHI, E .
EPILEPSIA, 1986, 27 (04) :323-330
[2]  
BLASCHKE TF, 1975, CLIN PHARMACOL THER, V17, P685
[3]   PRACTICAL CLINICAL-PHARMACOLOGY - THERAPEUTIC DRUG-MONITORING AND CLINICAL-TRIALS [J].
BRODIE, MJ ;
FEELY, J .
BRITISH MEDICAL JOURNAL, 1988, 296 (6629) :1110-1114
[4]  
BUCHANAN RA, 1970, NEUROLOGY, V21, P866
[5]  
CEREGHINO JJ, 1975, CLIN PHARMACOL THER, V18, P733
[6]   SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF CARBAMAZEPINE AND ITS PRINCIPAL METABOLITES IN HUMAN-PLASMA AND URINE [J].
CHELBERG, RD ;
GUNAWAN, S ;
TREIMAN, DM .
THERAPEUTIC DRUG MONITORING, 1988, 10 (02) :188-193
[7]   SODIUM VALPROATE - MONOTHERAPY AND POLYTHERAPY [J].
COVANIS, A ;
GUPTA, AK ;
JEAVONS, PM .
EPILEPSIA, 1982, 23 (06) :693-720
[8]   FORMATION OF ACTIVE METABOLITES OF ANTICONVULSANT DRUGS - A REVIEW OF THEIR PHARMACOKINETIC AND THEAPEUTIC SIGNIFICANCE [J].
EADIE, MJ .
CLINICAL PHARMACOKINETICS, 1991, 21 (01) :27-41
[9]   CARBAMAZEPINE IN THE TREATMENT OF EPILEPTIC DISORDERS - REPORT ON A LONG-TERM STUDY [J].
FROSCHER, W ;
EICHELBAUM, M ;
HILDENBRAND, G ;
HILDENBRAND, K ;
PENIN, H .
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 1982, 50 (12) :396-408
[10]  
FROSCHER W, 1979, FORTSCHR MED, V97, P1464